Buffett’s a believer: Berkshire bets $192M on Biogen ahead of key Alzheimer’s filing
Warren Buffett has bet big on Biogen. Buffet’s Berkshire Hathaway bought 648,447 shares of Biogen at a combined worth of $192.4M near the end of 2019, which they disclosed in a recent securities filing.
This comes as a surprise since Buffet isn’t often associated with biotech investments and it could be viewed as a risky move because Biogen is nearing a do-or-die FDA filing for controversial Eisai-partnered Alzheimer’s drug aducanumab.
